AU2018221822A1 - Anti-PD-L1 antibody treatment of bladder cancer - Google Patents

Anti-PD-L1 antibody treatment of bladder cancer Download PDF

Info

Publication number
AU2018221822A1
AU2018221822A1 AU2018221822A AU2018221822A AU2018221822A1 AU 2018221822 A1 AU2018221822 A1 AU 2018221822A1 AU 2018221822 A AU2018221822 A AU 2018221822A AU 2018221822 A AU2018221822 A AU 2018221822A AU 2018221822 A1 AU2018221822 A1 AU 2018221822A1
Authority
AU
Australia
Prior art keywords
subject
bladder cancer
binding fragment
antibody
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018221822A
Other languages
English (en)
Inventor
Yong BEN
John Andrew BLAKE-HASKINS
Mohammed Dar
Ashok Gupta
Tony Ho
Robert IANNONE
Xiaoping Jin
John KURLAND
Shannon Morris
Marlon REBELATTO
Li Shi
Jill WALKER
Magdalena ZAJAC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2018221822A1 publication Critical patent/AU2018221822A1/en
Priority to AU2025201227A priority Critical patent/AU2025201227A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018221822A 2017-02-16 2018-02-16 Anti-PD-L1 antibody treatment of bladder cancer Abandoned AU2018221822A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201227A AU2025201227A1 (en) 2017-02-16 2025-02-21 Anti-pd-l1 antibody treatment of bladder cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
US62/459,700 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201227A Division AU2025201227A1 (en) 2017-02-16 2025-02-21 Anti-pd-l1 antibody treatment of bladder cancer

Publications (1)

Publication Number Publication Date
AU2018221822A1 true AU2018221822A1 (en) 2019-09-26

Family

ID=63169615

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018221822A Abandoned AU2018221822A1 (en) 2017-02-16 2018-02-16 Anti-PD-L1 antibody treatment of bladder cancer
AU2025201227A Pending AU2025201227A1 (en) 2017-02-16 2025-02-21 Anti-pd-l1 antibody treatment of bladder cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201227A Pending AU2025201227A1 (en) 2017-02-16 2025-02-21 Anti-pd-l1 antibody treatment of bladder cancer

Country Status (12)

Country Link
US (2) US20190359715A1 (https=)
EP (1) EP3582805A4 (https=)
JP (2) JP2020507596A (https=)
KR (3) KR20190117014A (https=)
CN (2) CN110290803A (https=)
AU (2) AU2018221822A1 (https=)
CA (1) CA3052652A1 (https=)
EA (1) EA201991870A1 (https=)
IL (3) IL302777A (https=)
MA (1) MA47509A (https=)
SG (1) SG11201907211TA (https=)
WO (1) WO2018152415A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3142751T (pt) * 2014-05-13 2019-10-25 Medimmune Ltd Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células.
SG11201907211TA (en) * 2017-02-16 2019-09-27 Medimmune Llc Anti-pd-l1 antibody treatment of bladder cancer
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP4153783A1 (en) * 2020-05-21 2023-03-29 Astrazeneca AB Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma
US20250388678A1 (en) * 2024-06-25 2025-12-25 Astrazeneca Ab Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PT3142751T (pt) * 2014-05-13 2019-10-25 Medimmune Ltd Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células.
NZ733854A (en) * 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
JP7144935B2 (ja) * 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
SG11201907211TA (en) * 2017-02-16 2019-09-27 Medimmune Llc Anti-pd-l1 antibody treatment of bladder cancer

Also Published As

Publication number Publication date
EP3582805A4 (en) 2021-03-10
WO2018152415A1 (en) 2018-08-23
EP3582805A1 (en) 2019-12-25
SG11201907211TA (en) 2019-09-27
IL320916A (en) 2025-07-01
AU2025201227A1 (en) 2025-03-13
KR20190117014A (ko) 2019-10-15
IL268460A (en) 2019-09-26
US20220332828A1 (en) 2022-10-20
KR20230145547A (ko) 2023-10-17
CN110290803A (zh) 2019-09-27
CN118001389A (zh) 2024-05-10
US20190359715A1 (en) 2019-11-28
IL302777A (en) 2023-07-01
CA3052652A1 (en) 2018-08-23
JP2024038034A (ja) 2024-03-19
KR20250025517A (ko) 2025-02-21
JP2020507596A (ja) 2020-03-12
MA47509A (fr) 2019-12-25
EA201991870A1 (ru) 2020-02-12

Similar Documents

Publication Publication Date Title
US20220332828A1 (en) Anti-pd-l1 antibody treatment of bladder cancer
JP7641704B2 (ja) リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用
EP3601600A2 (en) Tumor burden as measured by cell free dna
WO2016030455A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
US20170275347A1 (en) Methods for identifying patients responsive to anti-pd-l1 antibody therapy
US20250340645A1 (en) Methods of treating tumor
CN114174538A (zh) 适合于免疫肿瘤学疗法的多肿瘤基因特征
US20240376206A1 (en) Compositions and methods for treating late stage lung cancer
CN114728070A (zh) 用于癌症疗法的复合生物标记物
CN114127315A (zh) 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN114174537A (zh) 细胞定位特征和组合疗法
WO2024196952A1 (en) Tumor subtype assessment for cancer therapy
WO2019164870A1 (en) Expression of signature mrnas for identifying patients responsive to anti-pd-l1 antibody therapy
WO2023019129A1 (en) Biomarkers for cd40 agonist therapy
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
JP2022517087A (ja) 癌の治療のためのｔｉｍ－３抗体および他のチェックポイント阻害剤との組み合わせ
WO2026052650A1 (en) Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment
TW202436335A (zh) 治療表現ｄｌｌ３的癌症之方法
CN118785922A (zh) 靶向dll3的癌症治疗

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted